Arife Ulas

Prof. Dr. Arife Ulas

Deparment of Medical Oncology, University of Health Sciences, Istanbul, İstanbul, Turkey (Türkiye)
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Journal of Gastric Cancer
Verified
Journal Article
Open access
PDF file
FTFatma Paksoy Turkoz
Fatma Paksoy Turkoz
MSMustafa Solak
Mustafa Solak
SKSaadettin Kilickap
Saadettin Kilickap
AUArife Ulas
Arife Ulas
OEOnur Esbah
Onur Esbah
SYSuayib Yalcin
Suayib Yalcin
Turkoz FP, et al. J Gastric Cancer. 2014 Sep;14(3):164-172. http://dx.doi.org/10.5230/jgc.2014.14.3.164

4 December 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AUArife Ulas
Arife Ulas
FTFatma Paksoy Turkoz
Fatma Paksoy Turkoz
KSKamile Silay
Kamile Silay
STSaadet Tokluoglu
Saadet Tokluoglu
NANilufer Avci
Nilufer Avci
NANecati Alkis
Necati Alkis
We aimed to establish a laboratory prognostic index (LPI) in advanced non-small cell lung cancer (NSCLC) patients based on hematologic and biochemical parameters and to analyze the predictive value of LPI on NSCLC survival. The study retrospectively reviewed 462 patients with advanced NSCLC diagnosed between 2000 and 2010 in a single institution. We developed an LPI that included serum levels of white blood cells (WBC), lactate dehydrogenase (LDH), albumin, calcium, and alkaline phosphatase (ALP), based on the results of a Cox regression analysis. The patients were classified into 3 LPI groups as follows: LPI 0: normal; LPI 1: one abnormal laboratory finding; and LPI 2: at least 2 abnormal laboratory findings. The median follow up period was 44 months; the median overall survival (OS) and median progression-free survival (PFS) were 11 and 6 months, respectively. A multivariate analysis revealed that the following could be used as independent prognostic factors: an Eastern Cooperative Oncology Group performance status score (ECOG PS) ≥2, a high LDH level, serum albumin 10.5 g/dL, number of metastases>2, presence of liver metastases, malignant pleural effusion, or receiving chemotherapy ≥4 cycles. The 1-year OS rates according to LPI 0, LPI 1, and LPI 2 were 54%, 34%, and 17% (p<0.001), respectively and 6-month PFS rates were 44%, 27%, and 15% (p<0.001), respectively. The LPI was a significant predictor for OS (Hazard Ratio (HR): 1.41; 1.05–1.88, p<0.001) and PFS (HR: 1.48; 1.14–1.93, p<0.001). An LPI is an inexpensive, easily accessible and independent prognostic index for advanced NSCLC and may be helpful in making individualized treatment plans and predicting survival rates when combined with clinical parameters.

15 August 2015 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
AUArife Ulas
Arife Ulas
ABAhmet Bilici
Ahmet Bilici
ADAyse Durnali
Ayse Durnali
STSaadet Tokluoglu
Saadet Tokluoglu
SASema Akinci
Sema Akinci
NANecati Alkis
Necati Alkis

18 March 2015 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
AUArife Ulas
Arife Ulas
KSKamile Silay
Kamile Silay
SASema Akinci
Sema Akinci
DDDidem Sener Dede
Didem Sener Dede
MAMuhammed Bulent Akinci
Muhammed Bulent Akinci
BYBulent Yalcin
Bulent Yalcin
Medication errors in oncology may cause severe clinical problems due to low therapeutic indices and high toxicity of chemotherapeutic agents. We aimed to investigate unintentional medication errors and underlying factors during chemotherapy preparation and administration based on a systematic survey conducted to reflect oncology nurses experience. This study was conducted in 18 adult chemotherapy units with volunteer participation of 206 nurses. A survey developed by primary investigators and medication errors (MAEs) defined preventable errors during prescription of medication, ordering, preparation or administration. The survey consisted of 4 parts: demographic features of nurses; workload of chemotherapy units; errors and their estimated monthly number during chemotherapy preparation and administration; and evaluation of the possible factors responsible from ME. The survey was conducted by face to face interview and data analyses were performed with descriptive statistics. Chi-square or Fisher exact tests were used for a comparative analysis of categorical data. Some 83.4% of the 210 nurses reported one or more than one error during chemotherapy preparation and administration. Prescribing or ordering wrong doses by physicians (65.7%) and noncompliance with administration sequences during chemotherapy administration (50.5%) were the most common errors. The most common estimated average monthly error was not following the administration sequence of the chemotherapeutic agents (4.1 times/month, range 1-20). The most important underlying reasons for medication errors were heavy workload (49.7%) and insufficient number of staff (36.5%). Our findings suggest that the probability of medication error is very high during chemotherapy preparation and administration, the most common involving prescribing and ordering errors. Further studies must address the strategies to minimize medication error in chemotherapy receiving patients, determine sufficient protective measures and establishing multistep control mechanisms.

6 December 2013 in Journal of Chemotherapy
Verified
Journal Article
Closed access
BCBulent Cetin
Bulent Cetin
MBMustafa Benekli
Mustafa Benekli
ITIbrahim Turker
Ibrahim Turker
LKLokman Koral
Lokman Koral
AUArife Ulas
Arife Ulas
SBSuleyman Buyukberber
Suleyman Buyukberber
Lapatinib is the first dual tyrosine kinase inhibitor of human epidermal growth factor receptor type 2 (HER2/neu) and epidermal growth factor receptor (EGFR). The present study evaluated the efficacy and tolerability of the combination of lapatinib and capecitabine in patients with metastatic breast cancer (MBC) who progressed after therapy with trastuzumab, a taxane and/or anthracycline. A total of 203 patients with a median age of 48 years (range: 25-82 years) were evaluated retrospectively in 11 centres between September 2007 and May 2011. All the patients had HER2-positive MBC progressing after trastuzumab and chemotherapy including an anthracycline and/or taxane. All patients were treated with the combination of lapatinib (1250 mg/day, continuously) and capecitabine (2000 mg/m(2) on days 1 through 14 of a 21-day cycle). Data on demographics, clinical outcome, and toxicity were collected for descriptive analyses. The median follow-up was 10·7 months (range: 1-40 months). An overall response rate (ORR) of 33·4% was achieved including 7 complete responses (CR, 3·4%), 61 partial responses (PR, 30·0%), and 44 stable disease (37·9%). Clinical benefit rate of 71·3% was achieved. Median progression-free survival (PFS) was 7 months (95% CI: 6-10 months), with a median overall survival (OS) of 15 months (95% CI: 12-18 months). The most common side effects were hand-foot syndrome (46·8%), nausea (42·3%), fatigue (42·2%), anorexia (38·5%), diarrhea (31·5%), and rash (29·6%). Grade 3-4 toxicities were identified as hand foot syndrome (7·9%), diarrhea (6·9%), fatigue (5·9%), and rash (5·4%). There were no symptomatic cardiac events. Lapatinib and capecitabine combination therapy is effective and well tolerated in patients with MBC who had progressive disease after trastuzumab, taxane, and/or anthracycline therapy, as evidenced by this retrospective evaluation. Toxicity was mild to moderate with low grade 3-4 toxicity.

15 May 2010 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
NANecati Alkis
Necati Alkis
ADAyse G. Durnali
Ayse G. Durnali
UAUlku Y. Arslan
Ulku Y. Arslan
MKMurat Kocer
Murat Kocer
FOFatih O. Onder
Fatih O. Onder
KAKadri Altundag
Kadri Altundag